NCT06109857 Bladder Bank (a Prospective Banking Study)
| NCT ID | NCT06109857 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Bladder Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2022-07-06 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2022-07-06 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study collects blood and urine samples from patients with bladder cancer to support the development of tests for early detection of bladder cancer.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * Patient has undergone office-based evaluation for hematuria \[computed tomography (CT), ultrasound, cystoscopy\] Exclusion Criteria: * Patient has known cancer outside of the target cancer 5 years prior to current collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible) * Patient has recurrent muscle invasive bladder cancer * Patient has ever been previously diagnosed with UTUC (upper tract urothelial carcinoma) prior to bladder resection * Patient has received chemotherapy class drugs for the treatment of non-target origin cancer in the 5 years prior to current collection * Patient has had any prior radiation therapy to the target lesion prior to current collection * Patient has had a biopsy to the target organ and/or lesion within 3 days before collection * Patient has undergone cystectomy or cystoprostatectomy * Patient has transurethral instrumentation (placement of urinary catheter) within 7 days prior to urine collection * Patient has had a urinary tract infection within 14 days prior to urine collection * Patient has chronic indwelling urinary catheter
Contact & Investigator
John B. Kisiel, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic in Rochester
Frequently Asked Questions
Who can join the NCT06109857 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bladder Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06109857 currently recruiting?
Yes, NCT06109857 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT06109857 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06109857 clinical trial?
NCT06109857 is sponsored by Mayo Clinic. The principal investigator is John B. Kisiel, MD at Mayo Clinic in Rochester. The trial plans to enroll 1,500 participants.